Rapid infliximab infusions in pediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 49, Issue 1, 2009, Pages 151-154

  Yeckes, Alyson R ^a   Hoffenberg, Edward J ^a,b  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Inflammatory bowel disease; Infliximab; Infusion; Pediatrics

Indexed keywords

AZATHIOPRINE; DIPHENHYDRAMINE; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG INFUSION; ENTERITIS; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; RETROSPECTIVE STUDIES;

EID: 67651056235     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31818e1914     Document Type: Article

References (11)

1. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
3. Centocor. Medication Guide Remicade. Centocor Inc, Malvern, PA; 2008.
4. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002; 97:2962-72.
5. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
6. van Vollenhoven RF, Gullstrom E, Klareskog L. Feasibility of 1 hour infliximab infusions. Ann Rheum Dis 2005;64:654.
7. Salzberg B, Kendall K. Successful 1 hour infusions ofinfliximab for Crohn's disease patients in an outpatient office setting. Gastroenterology 2004;126 (4 Suppl 2): A629.
8. Befrits R, Malmstrom L, Forsell A, et al. One hour infliximab infusion can replace two hour infusion in maintenance treatment of Crohns disease without shortcomings, in patients treated for up to three years [abstract]. Gastroenterology 2008;134:M1707.
9. Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002; 29:667-77.
10. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
11. Rosh JR, Oliva-Hemker M. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned. J Pediatr Gastroenterol Nutr 2007;44:165-7.